These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927 [TBL] [Abstract][Full Text] [Related]
3. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222 [TBL] [Abstract][Full Text] [Related]
4. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. Sierzega M; Pach R; Kulig P; Legutko J; Kulig J Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013 [TBL] [Abstract][Full Text] [Related]
6. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316 [TBL] [Abstract][Full Text] [Related]
7. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319 [TBL] [Abstract][Full Text] [Related]
8. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression. Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236 [TBL] [Abstract][Full Text] [Related]
10. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. Lansakara-P DS; Rodriguez BL; Cui Z Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Réjiba S; Bigand C; Parmentier C; Hajri A Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409 [TBL] [Abstract][Full Text] [Related]
14. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829 [TBL] [Abstract][Full Text] [Related]
15. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007 [TBL] [Abstract][Full Text] [Related]
16. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981 [TBL] [Abstract][Full Text] [Related]
17. In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells. Murata A; Nakata B; Komoto M; Hirata K; Kimura K; Amano R; Hirakawa K Hepatogastroenterology; 2013 Sep; 60(126):1484-7. PubMed ID: 23933942 [TBL] [Abstract][Full Text] [Related]
18. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. Liu Q; Song C; Li J; Liu M; Fu L; Jiang J; Zeng Z; Zhu H Med Oncol; 2022 Jun; 39(9):124. PubMed ID: 35716217 [TBL] [Abstract][Full Text] [Related]
19. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668 [TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]